We have updated our privacy policy and terms & conditions. Find out more here.
1
 

BEL Pharma and Bio-technology (BEPB)

Add to/Remove from a Portfolio  
1,922.33 +1.41    +0.07%
06/07 - Closed. Currency in EUR ( Disclaimer )
Type: Index
Market: Belgium
# Components: 8

  • Volume: -
  • Open: 1,915.71
  • Day's Range: 1,884.34 - 1,931.82
Start Trading
Pharma & Bio-tech 1,922.33 +1.41 +0.07%
Add to/Remove from a Portfolio  

Pharma & Bio-tech Overview

Prev. Close1,922.33
Volume-
Day's Range1,884.34 - 1,931.82
Open1,915.71
Average Vol. (3m)-
52 wk Range1630.66 - 2013.62
1-Year Return9.26%

BEL Pharma and Bio-technology News & Analysis

Related Articles

Most Active Stocks

  Name Last Prev. High Low Chg. % Vol. Time
UCB 65.59 65.59 65.99 64.26 +0.02% 218.72K 06/07  
Tigenix NV 0.7050 0.7050 0.7050 0.6820 +0.71% 157.92K 06/07  
Galapagos 46.595 46.595 47.290 44.590 +0.63% 120.22K 06/07  
Ablynx NV 11.320 11.320 11.395 10.905 +2.44% 112.61K 06/07  
Mdxhealth 4.512 4.512 4.548 4.410 +0.27% 99.10K 06/07  
Celyad 44.40 44.40 45.20 42.75 -0.10% 45.74K 06/07  
Thrombogenics 4.995 4.995 5.050 4.966 -1.09% 24.09K 06/07  
Tubize-Fin 54.900 54.900 55.550 54.030 -0.18% 6.30K 06/07  

Top Gainers

Name Last Chg. Chg. %
Ablynx NV 11.320 +0.270 +2.44%
Tigenix NV 0.7050 +0.0050 +0.71%
Galapagos 46.595 +0.290 +0.63%
Mdxhealth 4.512 +0.012 +0.27%
UCB 65.59 +0.01 +0.02%

Top Losers

Name Last Chg. Chg. %
Thrombogenics 4.995 -0.055 -1.09%
Tubize-Fin 54.900 -0.100 -0.18%
Celyad 44.40 -0.04 -0.10%
UCB 65.59 +0.01 +0.02%
Mdxhealth 4.512 +0.012 +0.27%
Powered By

Follow Top Signal Providers

Account Nickname Net Profit P/L % Win % Weeks
SignalKING $34,871.26 430.88% 46.92% 242 Follow
SignalMAX $38,814.10 268.25% 71.76% 96 Follow
SignalAlpha $5,730.29 234.85% 68.09% 58 Follow
SignalWave $3,428.37 227.16% 93.17% 38 Follow
SignalMixFX $17,815.52 200.99% 72.68% 38 Follow

My Sentiments

Add your sentiment:
or
 
Members' Sentiments:
Bullish
50%
Bearish
50%

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Add Chart to Comment
BEL Pharmaceuticals & Biotechnology
 
 
 
Are you sure you want to delete this chart?
 
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
 
Are you sure you want to delete this chart?
 
 
 

Successfully Reported

Thank you. This comment has been flagged for a moderator.
_touchLoadingMsg
 
 
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data .

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.